HC Wainwright Weighs in on AEON Biopharma, Inc.’s Q1 2025 Earnings (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for AEON Biopharma in a report issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.29) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma (NASDAQ:AEON) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter.

AEON Biopharma Price Performance

NASDAQ AEON opened at $6.54 on Thursday. The company’s fifty day simple moving average is $10.64 and its 200-day simple moving average is $7.78. AEON Biopharma has a 52 week low of $3.37 and a 52 week high of $17.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Atalaya Capital Management LP bought a new stake in shares of AEON Biopharma in the third quarter worth $19,827,000. Vanguard Group Inc. acquired a new stake in shares of AEON Biopharma in the 3rd quarter valued at about $1,085,000. Formidable Asset Management LLC bought a new position in shares of AEON Biopharma during the third quarter worth about $360,000. Finally, Northern Trust Corp grew its stake in AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock worth $359,000 after purchasing an additional 17,341 shares in the last quarter. Hedge funds and other institutional investors own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.